Journal of Oncology & Targeted Therapies

Biography

Dr. Praveen Kumar Neeli is an accomplished molecular oncologist and biomedical researcher with expertise in cancer immunotherapy, DNA-based vaccines, and translational oncology. He currently serves as Research Scientist I at the Moffitt Cancer Center, USA, where his research focuses on targeting stress signaling to enhance immunotherapy against metastatic breast cancer.

Dr. Neeli earned his Ph.D. in Applied Biology from the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad, where he investigated the role of metadherin isoforms in breast-cancer progression. His prior appointments include postdoctoral fellowships at the University of Texas MD Anderson Cancer Center and the Baylor College of Medicine, contributing to projects on CAR-T cell therapy and DNA vaccine development.

He has authored over 15 peer-reviewed articles in leading journals such as NPJ Vaccines, Journal of Hematology & Oncology, and Oncogene, and is a co-inventor on multiple international patents related to anti-inflammatory and siRNA-based therapeutics. His work has been cited over 560 times with an h-index of 11.

An active scientific communicator, Dr. Neeli serves as a Review Editor for Frontiers in Oncology and Academic Editor for the Journal of Cellular Immunology, while also reviewing manuscripts for more than 30 high-impact journals. His memberships include the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).

Research Interest

Cancer Immunotherapy • DNA and mRNA Vaccines • CAR-T Cell Therapy • Translational Oncology • Molecular Signaling • Drug Resistance Mechanisms • Computational Oncology • Nanomedicine